• 1
    McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25(Suppl 1): 38.
  • 2
    Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S17381.
  • 3
    Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 6573.
  • 4
    Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 152131.
  • 5
    Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008; 2: 14751.
  • 6
    Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 2002; 17(Suppl 3): 3337.
  • 7
    Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 127682.
  • 8
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. .
  • 9
    Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 131541.
  • 10
    Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical,and serology outcomes through 96 weeks. Hepatology 2008; 48: 99108.
  • 11
    Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 165665.
  • 12
    Colonno R, Levine S, Baldick J, et al. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology 2005; 42: 573A.
  • 13
    Matsuda M, Suzuki F, Suzuki Y, et al. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. J Gastroenterol 2004; 39: 3440.
  • 14
    Pollicno T, Isgro G, DiStefano R, et al. Variability of the HBV Pol gene reverse transcriptase domain in viral isolates from untreated and lamivudine-resistance chronic hepatitis B patients. Hepatology 2007; 46: 660A.
  • 15
    Pallier C, Castera L, Soulier A, Hézode C, Nordmann P, Dhumeaux D, Pawlotsky JM. Dynamics of hepatitis B virus resistance to lamivudine. J Virol 2006; 80: 64353.
  • 16
    Feeney E, Fanning LJ, Horgan M. Baseline genotypic resistance in untreated hepatitis B virus infection. Gastroenterology 2007; 132: 35A.
  • 17
    Lee CZ, Lee HS, Huang GT, Yang PM, Sheu JC. Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol 2006; 12: 53015.
  • 18
    Huang ZM, Huang QW, Qin YQ, et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 2005; 11: 86770.
  • 19
    Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol 2006; 21: 17838.
  • 20
    Jardi RR-FF, Buti M, Schaper M, Esteban R, Guardia J. Mutations at HBV-Polymerase gene associated with entecavir resistance in patients not undergoing entecavir therapy. Hepatology 2006; 44: 547A.
  • 21 . Hepatitis B virus drug resistance mutations. Last update 06/2007. Accessed 4/5/2009.
  • 22
    Aberle SW, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stöckl E. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol 2001; 39: 19724.
  • 23
    Ludwig AD, Goebel T, Adams O, et al. Primary resistance mutations against nucleos(t)ide analogues in treatment-naive patients with HBV infection. Hepatology 2008; 48: 701A.
  • 24 INNO-LiPA HBV DR v2. Last update 2/9/2009. Accessed 4/7/2009.
  • 25
    Sertoz RY, Erensoy S, Pas S, et al. Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother 2005; 17: 51420.
  • 26
    Hussain M, Chu CJ, Sablon E, Cursaro C, Andreone P, Lok AS. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol 2003; 41: 3699705.
  • 27
    Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, Lok AS. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006; 44: 10947.
  • 28
    Fung SK, Mazzulli T, El-Kashab M, Sherman M, Popovic V, Sablon E. Lamivudine-resistant mutation among treatment-naive patients is common and may be associated with treatment failure. Hepatology 2008; 48: 703A.
  • 29
    Lampertico PVM, Facchetti F, Puoti M, et al. Effectiveness of entecavir for the treatment of nuc-naive chronic hepatitis B patients: a large multicenter cohort study in clinical practice. Hepatology 2008; 48: 707A.
  • 30
    Margeridon-Thermet S, Shulman NS, Ahmed A, et al. Ultra-Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse-Transcriptase Inhibitor (NRTI)-Treated Patients and NRTI-Naive Patients. J Infect Dis 2009; 199: 127585.